Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
NCT06376734
Anxiety Disorders, Behavior
Sunnyvale, California, United States
View Trial DetailsNCT Number: NCT06874075
Offspring of parents with bipolar disorder (BD) and schizophrenia (SZ) are vulnerable and at high risk for these disorders. Despite the fact that positive family history of SZ or BD is the strongest predictor for the development of these severe mental illnesses, there is limited evidence assessing young adults of SZ and BP simultaneously with lack of detailed handling of similarities in risk and developmental trajectories during adolescence
Trial opening soon.
Get Notified6 year–18 year
All sexes
Observational
Offspring of parents with bipolar disorder (BD) and schizophrenia (SZ) are vulnerable and at high risk for these disorders. Despite the fact that positive family history of SZ or BD is the strongest predictor for the development of these severe mental illnesses, there is limited evidence assessing young adults of SZ and BP simultaneously with lack of detailed handling of similarities in risk and developmental trajectories during adolescence [1, 2]. SZ and BP are thought to share a common pathophysiological basis due to advances in the field of molecular genetics, which have yielded overlapping findings between the two disorders [3, 4]. The psychopathological base during adolescence is influenced by neurodevelopmental deviation prior to clinical onset of many severe mental illnesses [5, 6]. Moreover, the risk for developing psychopathology is high during adolescence and prodromal symptoms start even earlier and may overlap and are difficult to differentiate [5-8]. This has turned efforts towards identification and treatment of individuals at early stages of the illness, when first clinical manifestations emerge [8, 9].
Importantly, subthreshold symptoms of mania and depression along with unspecific behavioural, emotional, and cognitive manifestations are highly predictive of future manic and depressive episodes in BD as well as anxiety disorders, which is confirmed by the clinical staging perspective [10, 11]. Nevertheless, early recognition and intervention during the prodromal phase is still at an early stage in Sz [12] with limited research into valid prodromal criteria for BP [13]. Retrospective studies combining subjects with early-onset mania and early-onset first-episode psychosis have reported a similar pattern of neurodevelopmental and psychopathological features predating the appearance of more specific prodromal symptoms in both disorders [14, 15]. Therefore, the substantial overlap of symptoms in the initial phases suggests that early identification programmes should be aimed at detecting both the pre-psychotic and the pre-manic phases of SZ and BP [16]
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 months
Early recognition and intervention during the prodromal phase is still at an early stage in Sz [12] with limited research into valid prodromal criteria for BP [13]. Retrospective studies combining subjects with early-onset mania and early-onset first-episode psychosis have reported a similar pattern of neurodevelopmental and psychopathological features predating the appearance of more specific prodromal symptoms in both disorders [14, 15]. Therefore, the substantial overlap of symptoms in the initial phases suggests that early identification programmes should be aimed at detecting both the pre-psychotic and the pre-manic phases of SZ and BP [16].
Time frame: 6 months
overlap of symptoms in the initial phases suggests that early identification programmes should be aimed at detecting both the pre-psychotic and the pre-manic phases of schizophrenia and bipolar disorders.
Assiut University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06376734
Anxiety Disorders, Behavior
Sunnyvale, California, United States
View Trial DetailsNCT04395157
Anxiety Disorders, Generalized Anxiety Disorder
San Diego, California, United States
View Trial DetailsNCT06945627
Infections, Inflammation
Antwerp, Belgium
View Trial DetailsNCT05321602
Antipsychotic Agents, Central Nervous System Depression
Little Rock, Arkansas, United States
View Trial Details